Source:MarketUs
March27,202302:27ET
Alpha-1AntitrypsinDeficiencyAugmentationTherapyMarketSizetoHitAround USD2,517Mnby2032
AccordingtoMarket.us,theglobalalpha-1antitrypsindeficiency augmentationtherapy marketgrowthis drivenby the increaseintheprevalenceofGenetic andRespiratory diseases andmodernadvances intechnology anddiagnostic tools.
New York,March27,2023(GLOBE NEWSWIRE) -- Theglobalalpha-1antitrypsindeficiency augmentationtherapy marketsizeaccountedfor USD 1,413millionin2022andgrowthis estimatedtoaccelerateataCAGR of61%, registeringanincrementalrevenueofUSD 2517millionby 2032 Alpha-1antitrypsindeficiency canbedescribedas an inheritedconditionthatresults inalow or unpredictedlevelofalpha-1proteins synthesizedby theliver Itfrequently remains undiagnosedandaffects thelungs & liver,whichcanleadtopulmonary diseases
Togetadditionalhighlights onmajor revenue-generatingsegments,Requestanalpha-1antitrypsindeficiency augmentationtherapy marketsamplereportathttps://marketus/report/alpha-1-antitrypsin-deficiency-augmentationtherapy-market/request-sample/
Key Takeaway:
By type,theProlastinC segmentis expectedtogrow fastestduringtheforecastperiodof2023to2032. By end-user,thehospitalsegmentdominates themarketbecauseoftheemergenceofmultispecialty carein many countries.
In2022,NorthAmericadominatedtheglobalAATD augmentationtherapy marketwiththehighestrevenueshare of41%
Between2023-2032,theincreasingpopulationintheAsia-Pacific regionis expectedtohelpthemarket's growth
Patients withAATD needtobetreateddaily.For this reason,augmentationtherapy is thebestoption.Inaddition, severalpharmaceuticalcompanies areconductingresearchonnew andexistingmolecules,whichis expectedtodrive themarket's growthpositively.
Factors affectingthegrowthoftheAATD augmentationtherapy market
Severalfactors canaffectthegrowthoftheAATD augmentationtherapy market Someofthesefactors include:
Increasinggenetic disorders:Theprevalenceofgenetic disorders inthenew bornis increasingworldwide,which willboostthedemandfor AATD augmentationtherapy andwillhelpthemarketgrowthpositively
Diseasemanagement:AATD augmentationtherapy offers many healthbenefits likepreventinglungdestruction, correctingthedeficiency,etc Caregivers areadoptingthis therapy tomanagethediseaseinpatients,whichwill
boostthemarketgrowthduringtheforecastperiod
Researchanddevelopment:Manufacturers andresearchers aretryingtofindmoreflexibleways totreatpatients withAATD;this is expectedtoaffectthemarket's growthpositively
Technologicaladvancements:Modernadvances intechnology anddiagnostic tools for genetic diseases have madeitpossibletodiagnoseandtreatAATD withremarkablesuccess
Modifications inthehealthcaresector:Theincreasingnumber ofhospitals,improvementoftheir infrastructures, andadoptionofnobleways totreatpatients withAATD willpositively contributetothemarket's growth
Tounderstandhow our reportcanbringadifferencetoyour business strategy,Inquireaboutabrochure athttps://marketus/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-market/#inquiry
TopTrends inGlobalAATD AugmentationTherapy Market
Duringtheforecastperiod,themarketfor AATD augmentationtherapy is expectedtogrow duetoincreased investmentinR&D andthedevelopmentofcapablepipelineproducts.Recently,80new molecules,includinginhalation therapy,havebeentestedinclinicaltrials for alpha-1antitrypsindeficiencies treatment
Thekey players arekeentogainknowledgeaboutthemarketdynamics andcompetitivelandscaperegardingrecent& upcomingdevelopments,AATD prevalenceby major countries,andregulatory scenarios for major markets
MarketGrowth
Thewidevariety ofrisks andcomorbidities associatedwithAATD is acrucialfactor thatsignificantly impacts the growthofthealpha-1antitrypsindeficiencies (AATD) augmentationtherapy market Other lifestylefactors,suchas smokingandalcoholintakecanalsodirectly impactsevereoutcomes inAATD patients.Themarketfor alpha-1 antitrypsin(AATD) augmentationtherapy willbenefitfrom theprogressiverisk tolifeandlunghealth
RegionalAnalysis
NorthAmericadominates theglobalalpha-1antitrypsindeficiency (AATD) augmentationtherapy marketandwill continuetoholdthis positionduringtheforecastperiod NorthAmerica's dominanceis duetotheincreasingprevalence ofAATD intheUnitedStates andCanadaandthestrategic presenceofkey companies intheregion
Awareness programs thatfocus onthediagnosis andtreatmentofAATD ineachregionarekey tothesuccess,which willincreasethemarketgrowthover theforecastperiod
Changes inregulations andfactors atcountry levelaregoingtoaffectthemarket's futureandongoingtrends Thekey points thatcanpredictdifferentcountries' marketscenarios includecountry demographics,reimbursescenarios,new drugapproval,anddiseaseepidemiology
AsiaPacific marketgrowthis mainly duetotherisingbirthrateindevelopingcountries.Thegovernmentinitiatives in thediagnosis andtreatmentofgenetic disorders andcriticalillnesses is helpingtheAsiaPacific markettogrow ata substantialCAGR.This is expectedtogenerateasubstantialopportunity for marketplayers duringtheforecastperiod.
CompetitiveLandscape
Many marketplayers areinvolvedindevelopingnew augmentationtherapy,analysis ofmarketscenarios,and increasedinvestmentinresearchanddevelopment.Tocreateacompetitiveenvironment,many key players are collaborating,modifyingtechnology,improvingdiagnostic techniques & treatmentmethods,andlaunchingnew products.Marketgrowthis further stimulatedby therisingprevalenceofrespiratory diseases andincreased investments madeby major players
S.A.KamadaLtd.,Grifols S.A.,Shireplc (Baxalta),TevaPharmaindustries ltd.,andCSLLimitedarethekey players inthemarketandcontributedthemajor revenueshareinthemarket Grifols S A is thelargestshareholder inAATD augmentationtherapy marketowingtothesales ofProlastic C.Itis expectedthatGrifols willremaintopplayer during theforecastperiod As thegovernments ofmajor markets involvedintheexpansionandmaintenanceofAATD augmentationtherapy,moreplayers areexpectedtoenter inAATD augmentationtherapy market.These developments arelikely todrivethegrowthofAATD augmentationtherapy market
MarketDrivers
SevereAATD is theleadingcausethatrequirehospitaltreatment Many treatmentoptions areavailablefor AATD patients,includingbronchodilators,proteinaseinhibitors,oxygentherapy,andcorticosteroids.But,augmentation therapy is mostpreferredinAATD patients becauseofits low mortality rate,whichis akey driver for themarket growth.
Other factors thatdrivethemarketgrowthincludeawareness programs by governments andkey players,improved diagnostic tools,andanincreaseinimprovedfacilities inthehospitals
Augmentationtherapy has beenshowntobeeffectiveinreducingmortality rates inpatients withAATD.Italsooffers healthbenefits likepreventionoflungdestruction,theelevationofA1ATplasmaandlunginterstititis,correctionof deficiencies,as wellas awell-provensafety profileandefficacy profile
Modificationandreductionofsideeffects for augmentationtherapy inAATD patients is expectedtoaugmentthe marketgrowth.
MarketRestraints
Augmentationtherapy canalsobecalledreplacementtherapy Augmentationtherapy canonly slow downthe progressionoflungdiseasebutcannotcureitpermanently Itis notpossibletoreversethelungdamageduringthe treatment Anintravenous catheter is usedtoadminister IV AAT This procedureis usually doneonceper week for a lifetime This repeatedinsertionofneedles andcatheters cancausedamagetotheveins However,itcanbeavoided by takingproper careandunder supervisionofaqualifiedandexperiencedhealthcaregiver
MarketOpportunities
Augmentationtherapy involves theadministrationofAlpha-1Antitrypsin(AAT) from ahealthy donors toAATD patients This procedureincreasetheAlpha-1Antitrypsinlevelinpatients withemphysemaor severeAATD.However thereis unmetneedinemergingcountries whichmakes augmentationtherapy aprofitableandlucrativeoptionandcreates many opportunities for new marketplayers toenter.
A growingawareness ofaugmentationtherapy,new drugdevelopments,theinnovationofnew diagnostic methods, andinvolvementby privateandpublic authorities areincreasingtheopportunities for marketplayers toconcentrateon this market
Grow your profitmarginwithMarket.us - PurchaseThis Premium Reportathttps://market.us/purchase-report/? report id=95351
ReportSegmentationoftheAATD AugmentationTherapy Market
TypeInsight
Basedontype,thesegments ofaugmentationtherapy includeProlastinC,AralastNP,Glassia,and Zemaira/Respreeza.ProlastinC accountedfor thelargestmarketshareover theforecastperiod.Itis expectedto continuetobeadominantproductover thenextfew years
Respreezahas beenapprovedby Europeanregulatory authorities andis expectedtogrow atahighCAGR duringthe forecastperiod
Glassiais themostcommonmedicineusedinadults sufferingfrom emphysema(lungdiseases) duetoAlpha-1 AntitrypsinDeficiency (AAT) Itis givenintravenously atroom temperatureataratenottoexceed02mL/kg
AralastNP is alsousedtotreatadults withemphysemaandis synthesizedfrom HumanAlpha-1ProteaseInhibitor
ProlastinC andGlassiaaretwoofthemostpopular treatmentoptions for AATD augmentationtherapy.This positively drives thegrowthoftheglobalalpha-1antitrypsindeficiency augmentationtherapy market
End-User Insight
Theglobalalpha-1antitrypsindeficiency augmentationtherapy marketcanbedividedintothreesegments basedon end-user:hospitals,specialty clinics,andothers Thehospitalsegmentholds thelargestmarketshare Hospitals are themostpreferredfor thetreatmentofAATD indevelopingcountries This is duetotheadventofmultispecialty healthcareindifferentcountries andgrowinginvestments by privateandpublic players inthehealthcaresector
TheAATD augmentationmarket's hospitalsegmentis growingduetotheavailability ofbetter andcompletecareof patients comparetoother healthcarefacilities
As thenumber ofcongenitaldisorders is increasing,pharmacies mustensurethatmedicines areavailablefor AATD This is expectedtoresultinhigher revenueduringtheforecastperiodfor thepharmacy segment.
For moreinsights onthehistoricalandForecastmarketdatafrom 2016to2032- downloadasamplereport athttps://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-market/request-sample/
MarketSegmentation
By ProductTypeProlastinC
AralastNP
Glassia Zemaira/Respreeza
By End-UserHospitals
Specialty Clinics
Others
By GeographyNorthAmerica
TheUS
Canada
Mexico
WesternEurope
Germany
France
TheUK
Spain
Italy
Portugal
Ireland
Austria
Switzerland
Benelux
Nordic
RestofWesternEurope
EasternEurope
Russia
Poland
TheCzechRepublic
Greece
RestofEasternEurope
APAC
China
Japan
SouthKorea
India
Australia& New Zealand
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
RestofAPAC
LatinAmerica
Brazil
Colombia
Chile
Argentina
CostaRica
RestofLatinAmerica
MiddleEast& Africa
Algeria Egypt
Israel
Kuwait
Nigeria
SaudiArabia
SouthAfrica
Turkey
UnitedArabEmirates
RestofMEA
Key MarketPlayers
Grifols,S.A.
KamadaPharmaceuticals
CSLLimited
TakedaPharmaceuticalCompany Limited
TevaPharmaceuticalIndustries ltd.
GlaxoSmithKlinePLC
ArrowheadPharmaceutical,Inc
LFB Biomedicaments S A
MereoBioPharmaGroupplc
IntelliaTherapeutics,Inc
Inhibrx,Inc
CentessaPharmaceuticals
KrystalBiotech
Beam Therapeutics
LogicBioTherapeutics,Inc
Apic Bio
Pfizer Inc
Other Key Players
RecentDevelopmentoftheAATD AugmentationTherapy Market
Grifols S A launchedAlfacareinNovember 2018 This therapy program provides trainingandcounselingto patients withAlpha-1AntitrypsinDeficiency.Itwas observedthatthepatients withAATD wereabletoadoptnew lifestyles andmanagetheir diseasebetter
KamadaPharmaceuticals was approvedfor glassia,anAATD drugfor self-infusion,inJune2016.This allows patients toadminister their owndrugs
ExploreMoreRelatedReports
GeneTherapy Marketsizeis expectedtobewortharoundUSD 497Bnby 2032ataCAGR of25%forecast period2023- 2032
Stem Celltherapy Marketsizeis expectedtobewortharoundUSD 445Bnby 2032ataCAGR of153% forecastperiodfrom 2022to2032
Cancer Immunotherapy Marketsizeis expectedtobewortharoundUSD 674Bnby 2032ataCAGR of138% forecastperiodfrom 2022-2032
Electromagnetic Therapy DeviceMarketis projectedtobeUSD 3476Mnin2022toreachUSD 6000Mnby 2032ataCAGR of69%
Allergy Immunotherapies (Allergy Immunotherapy) Marketis expectedtogrow ataCAGR 810%over thenext tenyears,andwillreachatUS$4280Mnin2033,from US$1930Mnin2023
Brachytherapy Marketwas valuedatUSD 8442millionin2021andis expectedtoreachUSD 19billionby 2032 ataCAGR of79%
Celltherapy Marketwas valuedatUSD 10,2278millionby 2021 This growthratewillincreaseataCAGR of 133%between2023-2032
AboutUs:
MarketUS (Poweredby Prudour PvtLtd) specializes inin-depthmarketresearchandanalysis andhas beenproving its mettleas aconsultingandcustomizedmarketresearchcompany,apartfrom beingamuchsought-after syndicatedmarketresearchreport-providingfirm MarketUS provides customizationtosuitany specific or unique requirementandtailor-makes reports as per request.Wegobeyondboundaries totakeanalytics,analysis,study,and outlook tonewer heights andbroader horizons
Follow Us onLinkedIn| Facebook | Twitter
Our Blog: https://scoopmarketus/